View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Immunity Article Mammalian Target of Rapamycin Controls Dendritic Cell Development Downstream of Flt3 Ligand Signaling Taheri Sathaliyawala,1 William E. O’Gorman,2 Melanie Greter,3 Milena Bogunovic,3 Vjollca Konjufca,4 Z. Esther Hou,1 Garry P. Nolan,2 Mark J. Miller,4 Miriam Merad,3 and Boris Reizis1,* 1Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA 2Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305, USA 3Department of Gene and Cell Medicine and the Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029, USA 4Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110-1093, USA *Correspondence:
[email protected] DOI 10.1016/j.immuni.2010.09.012 SUMMARY present antigens on MHC class I molecules (den Haan et al., 2000). Consistent with these properties, CD8+ DCs are critical Dendritic cells (DCs) comprise distinct functional for the capture, transport, and presentation of intracellular path- À subsets including CD8 and CD8+ classical DCs ogens such as Listeria monocytogenes (LM) (Neuenhahn et al., (cDCs) and interferon-secreting plasmacytoid DCs 2006). The same dichotomy was documented in tissues, in which + (pDCs). The cytokine Flt3 ligand (Flt3L) controls the the CD103 cDC subset serves as a functional and genetic coun- + development of DCs and is particularly important terpart of CD8 cDCs (Bedoui et al., 2009b; Bogunovic et al., for the pDC and CD8+ cDC and their CD103+ tissue 2009; Ginhoux et al., 2009; Varol et al., 2009).